NCT03298672View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

PHASE1CompletedINTERVENTIONAL

Enrollment

88

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

September 5, 2019

Study Completion Date

September 5, 2019

Conditions

Alzheimer Disease

Interventions

DRUG

NDX-1017

Solution of NDX-1017 for subcutaneous injection

DRUG

Placebo

Placebo solution for subcutaneous injection

Trial Locations (1)

07103

Biotrial Inc., Newark

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Alzheimer's Drug Discovery Foundation

OTHER

collaborator

Biotrial Inc.

UNKNOWN

lead

Athira Pharma

INDUSTRY

NCT03298672 - Safety, Tolerability, and Pharmacokinetics Study of NDX-1017 | Biotech Hunter | Biotech Hunter